Clinical Cardiology
RSSArticles
-
Utility of Non-traditional Risk Factors
Adding additional risk factors not in the pooled risk equation to low-risk subjects identified a sub-group with an observed event rate > 7.5% who may warrant statin therapy.
-
Temporal Relationship Between Atrial Fibrillation and Ischemic Stroke?
Multiple hours of atrial fibrillation had a strong but transient effect raising stroke risk, suggesting that a strategy of intermittent targeted usage of rapidly acting anticoagulants might merit further consideration by a randomized trial.
-
Aortic Valve Replacement in Asymptomatic Patients: Can Registry Data Replace Randomized, Controlled Trials?
Patients with severe asymptomatic aortic stenosis managed conservatively have “dismal” outcomes in real-world practice.
-
Optimal Beta-blocker Dose Post-MI
ABSTRACT & COMMENTARY: A look at survival rates using high and low doses of beta blockers.
-
Blood Pressure Targets in Flux Again
Trial could be a game changer if the results are robust.
-
Finally, a Positive Outcomes Study for Platelet Function Testing
Platelet function testing-defined clopidogrel nonresponsiveness can be overcome by prasugrel treatment, and that this is a modifiable risk factor whose treatment can improve outcomes.
-
Slow Down, Save Lives? Rate Control in Atrial Fibrillation
Atrial fibrillation patients receiving beta-blockers or calcium channel blockers had lower risk of mortality compared to those not taking rate-control drugs, with the lowest mortality rate in the beta-blocker group, while digoxin use was associated with a higher risk of mortality.
-
Beta-blocker Dose More Important Than Heart Rate in Systolic Heart Failure
In chronic heart failure with reduced ejection fraction, titrating beta-blocker doses may confer a greater benefit than reducing heart rate.
-
Reduced Leaflet Motion in Bioprosthetic Valves
ABSTRACT & COMMENTARY: It's in a significant proportion of surgical and transcatheter bioprosthetic aortic valves by volume-rendered CT scans.
-
Two Drugs Better Than One for Pulmonary Arterial Hypertension
Among subjects with pulmonary arterial hypertension who are treatment naïve, initial combination therapy with tadalafil and ambrisentan is associated with significantly lower risk of clinical failure than initial monotherapy with either tadalafil or ambrisentan.